Table 1.
Disease Characteristics and Induction Response by Quartile of CD33 Expression
| CD33 Q1 (n = 208) | CD33 Q2 (n = 205) | CD33 Q3 (n = 206) | CD33 Q4 (n = 206) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | No. | % | No. | % | No. | % | No. | % | P |
| Sex | |||||||||
| Male | 110 | 53 | 105 | 51 | 96 | 47 | 108 | 52 | .563 |
| Female | 98 | 47 | 100 | 49 | 110 | 53 | 98 | 48 | |
| Treatment arm | |||||||||
| No-GO | 115 | 55 | 99 | 48 | 96 | 47 | 101 | 49 | .310 |
| GO | 93 | 45 | 106 | 52 | 110 | 53 | 105 | 51 | |
| Cytogenetics | |||||||||
| Normal | 28 | 14 | 34 | 17 | 60 | 30 | 60 | 30 | < .001 |
| t(8;21) | 64 | 32 | 40 | 20 | 13 | 6 | 0 | 0 | < .001 |
| inv(16) | 31 | 15 | 34 | 17 | 20 | 10 | 11 | 5 | .001 |
| t(9;11)/11q23 | 16 | 8 | 32 | 16 | 50 | 25 | 66 | 33 | < .001 |
| t(6;9)(p23;q34) | 2 | 1 | 0 | 0 | 5 | 2 | 5 | 2 | .112 |
| Monosomy 7 | 6 | 3 | 5 | 3 | 2 | 1 | 3 | 1 | .462 |
| del(7q) | 4 | 2 | 3 | 2 | 3 | 1 | 2 | 1 | .880 |
| -5/5q- | 1 | 0 | 6 | 3 | 4 | 2 | 0 | 0 | .035 |
| +8 | 12 | 6 | 7 | 4 | 16 | 8 | 17 | 8 | .183 |
| Other | 38 | 19 | 36 | 18 | 28 | 14 | 38 | 19 | .505 |
| Unknown | 6 | 8 | 5 | 4 | |||||
| FLT3/ITD status | |||||||||
| ITD+ | 23 | 11 | 22 | 11 | 45 | 22 | 46 | 23 | < .001 |
| ITD− | 183 | 89 | 179 | 89 | 157 | 78 | 156 | 77 | |
| Unknown | 2 | 4 | 4 | 4 | |||||
| CEBPA status | |||||||||
| CEBPA mutant | 10 | 5 | 17 | 8 | 16 | 8 | 6 | 3 | .065 |
| CEBPA WT | 197 | 95 | 185 | 92 | 186 | 92 | 197 | 97 | |
| Unknown | 1 | 3 | 4 | 3 | |||||
| NPM1 status | |||||||||
| NPM1 mutant | 5 | 2 | 11 | 5 | 17 | 8 | 31 | 15 | < .001 |
| NPM1 WT | 202 | 98 | 190 | 95 | 185 | 92 | 172 | 85 | |
| Unknown | 1 | 4 | 4 | 3 | |||||
| Risk group (cyto/molecular) | |||||||||
| Intermediate | 73 | 36 | 80 | 40 | 108 | 53 | 129 | 63 | < .001 |
| Low | 105 | 51 | 99 | 50 | 60 | 30 | 43 | 21 | < .001 |
| High | 27 | 13 | 20 | 10 | 34 | 17 | 33 | 16 | .189 |
| Unknown | 3 | 8 | 4 | 1 | |||||
| Induction I response | |||||||||
| CR | 153 | 74 | 151 | 75 | 143 | 70 | 145 | 73 | .701 |
| Not in CR | 54 | 26 | 50 | 25 | 61 | 30 | 54 | 27 | |
| Not evaluable | 1 | 4 | 2 | 7 | |||||
| Induction II response | |||||||||
| CR | 183 | 90 | 169 | 87 | 171 | 86 | 169 | 86 | .684 |
| Not in CR | 21 | 10 | 26 | 13 | 27 | 14 | 27 | 14 | |
| Not evaluable | 4 | 10 | 8 | 10 | |||||
| No-GO patients only | |||||||||
| Induction I response | |||||||||
| CR | 84 | 73 | 73 | 74 | 59 | 62 | 65 | 67 | .208 |
| Not in CR | 31 | 27 | 25 | 26 | 36 | 38 | 32 | 33 | |
| Not evaluable | 0 | 1 | 1 | 4 | |||||
| Induction II response | |||||||||
| CR | 101 | 90 | 82 | 84 | 73 | 81 | 84 | 88 | .228 |
| Not in CR | 11 | 10 | 16 | 16 | 17 | 19 | 11 | 12 | |
| Not evaluable | 3 | 1 | 6 | 6 | |||||
| GO patients only | |||||||||
| Induction I response | |||||||||
| CR | 69 | 75 | 78 | 76 | 84 | 77 | 80 | 78 | .945 |
| Not in CR | 23 | 25 | 25 | 24 | 25 | 23 | 22 | 22 | |
| Not evaluable | 1 | 3 | 1 | 3 | |||||
| Induction II response | |||||||||
| CR | 82 | 89 | 87 | 90 | 98 | 91 | 85 | 84 | .065 |
| Not in CR | 10 | 11 | 10 | 10 | 10 | 9 | 16 | 16 | |
| Not evaluable | 1 | 9 | 2 | 4 | |||||
Abbreviations: CR, complete remission; cyto, cytogenetic; GO, gemtuzumab ozogamicin; ITD, internal tandem duplication; Q, quartile; WT, wild type.